Core Viewpoint - The completion of patient enrollment for the clinical study of GPN00289, a temperature-sensitive embolic agent for primary liver cancer, marks a significant advancement in the company's research and development in the field of nuclear medicine for tumor treatment [1][4]. Group 1: Product Overview - GPN00289 is an innovative temperature-sensitive embolic material recognized by the National Medical Products Administration of China, designed for treating hypervascular benign and malignant tumors [2]. - The product features temperature responsiveness and high plasticity, allowing it to transition from liquid to solid state, effectively embolizing various blood vessels [2]. - GPN00289 combines the advantages of liquid and solid embolization, addressing the limitations of current transcatheter arterial chemoembolization (TACE) methods [3]. Group 2: Market Context - According to GLOBOCAN 2022, there are approximately 870,000 new liver cancer cases globally, with around 760,000 deaths, highlighting the critical need for effective treatment options [3]. - In China, liver cancer accounts for about 370,000 new cases and 320,000 deaths annually, representing 42.5% and 42.1% of global figures, respectively [3]. - The prognosis for liver cancer patients is poor, with a high recurrence rate post-surgery and a low five-year survival rate, emphasizing the demand for effective treatment methods [3]. Group 3: Strategic Development - The company holds global rights to GPN00289 and aims to advance its global registration and development, particularly in collaboration with the innovative internal radiotherapy drug, Yttrium-90 microspheres [4]. - The company has established a comprehensive nuclear medicine industry chain, including research, production, distribution, and sales, with over 900 employees globally [4][8]. - The company is actively developing a pipeline of innovative products, with 15 products in the registration stage, covering multiple cancer types and utilizing various radioactive isotopes [5]. Group 4: Infrastructure and Innovation - The company has completed a state-of-the-art radioactive drug research and production base in Chengdu, China, which is the first of its kind to cover the entire nuclear medicine industry chain [8]. - This facility enhances the company's ability to produce a wide range of products autonomously, addressing previous reliance on imports and ensuring high standards of safety and quality [8]. - The company emphasizes innovation and advanced technology development, focusing on unmet clinical needs and aiming to provide diverse treatment options for patients globally [9].